Core Viewpoint - Chaoyue Eye Care (02219.HK) reported a revenue of 1.405 billion RMB for the fiscal year 2024, reflecting a year-on-year growth of 2.6%, while adjusted net profit reached 203 million RMB with a net profit margin of 14.4% [1] Financial Performance - The company achieved a net cash flow from operating activities of 354 million RMB, indicating strong cash management capabilities [1] - The gross profit margin was maintained at 43.5% despite industry policy adjustments, supported by cost control and process optimization [2] - A dividend of 0.25 HKD per share was declared, with a high payout ratio of 80%, showcasing stable cash flow management [3] Business Segments - Basic ophthalmology revenue increased by 6.7% to 698 million RMB, driven by optimized diagnostic services and personalized customer engagement [1] - Consumer ophthalmology revenue slightly decreased by 0.4% to 706 million RMB, influenced by overall economic downturn, with stable pricing adjustments [1] - The number of outpatient and inpatient visits grew by 2.9% and 71.2% respectively, due to the "regional center hospital + satellite clinic" management model [1] Strategic Initiatives - The company is advancing its "North China consolidation + Yangtze River Delta breakthrough" regional strategy, operating 31 eye hospitals and 29 optical centers across seven provinces and autonomous regions [1] - Chaoyue Eye Care is enhancing its application of artificial intelligence in diagnostic processes and service efficiency [1] - The company is focusing on expanding its network through new establishments and acquisitions while strengthening its smart healthcare system [1] Market Outlook - The high demand in the ophthalmology sector is supported by an aging population and increasing myopia prevention needs among youth, which drives the demand for basic eye care services [2] - The trend of consumption upgrades is gradually releasing the market potential for high-end services such as refractive surgery [2] - The company is adapting to the policy environment through its "Excellence Program," optimizing procurement processes and enhancing service efficiency [2] Social Responsibility - In 2024, the company will enhance its social value through public welfare projects, providing amblyopia screening and treatment for underprivileged children in Inner Mongolia [2] - Participation in the "Belt and Road Brightness Action" international medical assistance and conducting over a hundred eye health awareness activities, reaching thousands of families [2] Research and Development - The company led five research projects, published 18 papers, and obtained five patents during the year, laying the groundwork for technological upgrades [3] - The "Phoenix Plan" for human resources aims to attract high-end talent and promote integrated development of science, education, and research [3] Future Focus - Management plans to concentrate on three main areas by 2025: deepening the layout in North China and the Yangtze River Delta, expanding the scope of consumer eye care services, and advancing ESG (Environmental, Social, and Governance) system construction [3]
朝聚眼科2024年业绩稳健增长，基础眼科服务成核心增长点